DiaSorin first-half revenues surge on non-COVID testing

By LabPulse.com staff writers

August 4, 2022 -- DiaSorin this week reported revenues of 685.4 million euros ($699.9 million) for the first half of 2022, an increase of 33% year-over-year.

Revenues were driven in part by sales of products from Luminex, acquired last July for $1.8 billion.

The Saluggia, Italy-based diagnostic testing company also saw gains its sales of its immunodiagnostic and molecular diagnostic products, but its revenues were partly offset by a decline in COVID-related sales.

Without including revenues from COVID products, immunodiagnostics revenues in the first half of the year were 332.6 million euros, up 10% from 302.4 million euros in the prior-year period. These revenues were mainly due to a "solid performance" from latent tuberculosis, infectious disease, and gastrointestinal panel tests, the firm said.

Ex-COVID molecular diagnostics revenues were 96.7 million euros, up almost 171% from 35.7 million euros in the prior-year period.

Luminex licensed technologies revenues were 106.4 million euros compared to no recorded revenues in the prior half-year, and COVID-19 revenues were 149.8 million euros, down 15.5% compared to 177.3 million euros in the prior-year period.

For the first half of 2022, DiaSorin posted a net profit of 140.8 million euros compared to 150 million euros in the prior half-year.

For full-year 2022, DiaSorin anticipates 2% year-over-year revenue growth and 200 million euros in COVID-related revenues, with about a 24% rise in revenues unrelated to COVID testing.

DiaSorin nabs FDA clearance for infectious disease blood test
Saluggia, Italy-based DiaSorin on Friday announced that it has obtained U.S. Food and Drug Administration (FDA) clearance for the Liaison MeMed BV, its...
DiaSorin updates assay to detect omicron variant
DiaSorin Molecular recently released an updated version of its Simplexa Variants Direct assay to detect mutations associated with the new omicron variant...
Qiagen, DiaSorin partner on TB screening
The U.S. Food and Drug Administration has approved Qiagen's Liaison QuantiFeron-TB Gold Plus assay for use on DiaSorin's automated Liaison XS platform....
Qiagen, DiaSorin debut Lyme disease assay
Qiagen and DiaSorin announced the launch of the Liaison LymeDetect assay for early detection of the Lyme Borreliosis infection. The test detects immunoglobulin...

Copyright © 2022 LabPulse.com

Last Updated lo 8/4/2022 10:06:06 AM